September 2nd 2025
Supported by Phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.
August 29th 2025
Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.
August 29th 2025
New authorization limits shots to adults ≥65 and individuals with underlying health conditions, with ACIP set to review guidance and insurance coverage implications.
August 22nd 2025
New data show consistent late-summer and winter surges, reinforcing the need for seasonal vaccine timing and focused protection for high-risk groups.
August 22nd 2025
STOP-PASC substudy results find digital biometrics align with symptom burden, supporting their use as objective measures in long COVID research.
CDC Modifies Interval Time Between Dosing for mRNA COVID-19 Vaccines to 6 Weeks
January 22nd 2021If the current recommended dosing schedules for the vaccines are not “feasible,” then the agency said vaccines may be scheduled for administration up to 42 days between the first and second doses.
Read More
Assessment Finds More Systematic Reviews than Primary Studies on COVID-19
January 20th 2021An assessment of literature on imaging findings of children with coronavirus disease 2019 (COVID-19) found more systematic reviews than primary studies, raising concerns about wasteful repetition, according to a research letter in JAMA Network Open.
Read More
2 Commerce Drive
Cranbury, NJ 08512